Fennec Pharmaceuticals Inc. reported its financial results for the first quarter ended March 31, 2025. The company achieved total net revenues of $8.8 million, marking an 18% increase compared to the same period in 2024, where revenues stood at $7.4 million. This growth was driven by an increase in PEDMARK product sales, particularly across new accounts in the adolescent and young adult $(AYA)$ population. Significantly, the company's refined and targeted sales strategy, coupled with enhanced patient support services through the revamped Fennec HEARS™ program, contributed to this positive momentum. Additionally, PEDMARQSI is now commercially available in Germany and the United Kingdom, expanding Fennec Pharmaceuticals' market reach. The company's operating expenses reflected a decrease in the cost of products sold, which was $373,000 compared to $550,000 in the previous year. Research and development expenses increased slightly to $94,000 from $3,000 in the first quarter of 2024. Fennec Pharmaceuticals continues to participate in key investor conferences to engage with stakeholders and discuss its business strategies.